Researchers developed a new algorithm that can use a single OCT scan to predict whether a patient with diabetic macular edema is likely to respond to anti-VEGF treatments. They tested it on pretreatment OCT images (top row) and used post-treatment OCT images (bottom row) to track response to treatment. Case 24 and 36 responded to treatment.
Credit: Sina Farsiu, Duke University
New algorithm poised to help doctors individualize treatment for diabetic macular edema
A new approach that uses artificial intelligence to analyze retinal images could one day help doctors select the best treatment for patients with vision loss from diabetic macular edema. This diabetes complication is a major cause of vision loss among working-age adults.
Anti-vascular endothelial growth factor (VEGF) agents are widely used as the first line of therapy for diabetic macular edema, but they don’t work for everyone. There’s a need to identify who would benefit from the therapy because it requires multiple injections that are costly and burdensome for both patients and physicians.
“We developed an algorithm that can be used to automatically analyze optical coherence tomography (OCT) images of the retina to predict whether a patient is likely to respond to anti-VEGF treatments,” said research team leader Sina Farsiu from Duke University. “This research represents a step toward precision medicine, in which such predictions help clinicians better select first-line therapies for patients based on specific disease conditions.”
In The Optical Society (OSA) journal Biomedical Optics Express, Farsiu and colleagues show that the new algorithm can analyze just one pre-treatment volumetric scan to accurately predict whether a patient is likely to respond to anti-VEGF therapy.
“Our approach could potentially be used in eye clinics to prevent unnecessary and costly trial-and-error treatments and thus alleviate a substantial treatment burden for patients,” Farsiu said. “The algorithm could also be adapted to predict therapy response for many other eye diseases, including neovascular age-related macular degeneration.”
Predicting treatment response
The algorithm developed by the researchers is based on a novel convolutional neural network (CNN) architecture, a type of artificial intelligence that can analyze images by assigning importance to various aspects or objects. They used the algorithm to examine images acquired with OCT, a noninvasive technology that produces high-resolution cross-sectional retinal images and is the standard of care for assessing and treating many eye conditions.
“Unlike previously developed approaches, our algorithm requires OCT images from only a single pretreatment timepoint,” said Reza Rasti, first author of the paper and a postdoctoral scholar in Farsiu’s laboratory. “There’s no need for time-series OCT images, patient records or other metadata to predict therapy response.”
The new algorithm preserves and highlights global structures in the OCT image while enhancing local features from diseased regions to efficiently use retinal thickness information. To help with treatment decision making, the researchers incorporated an additional step that looks for CNN-encoded features that are highly correlated with anti-VEGF response.
Testing the algorithm
The researchers tested their new algorithm with OCT images from 127 patients who had been treated for diabetic macular edema with three consecutive injections of anti-VEGF agents. They applied the algorithm to analyze OCT images taken before the anti-VEGF injections, then compared the algorithm’s predictions to OCT images taken after anti-VEGF therapy to confirm whether the therapy improved the condition.
Based on the results, the researchers calculated that the algorithm would have an 87 percent chance of correctly predicting who would respond to treatment. It exhibited an average precision and specificity of 85 percent and a sensitivity of 80 percent.
Next, the researchers plan to confirm and extend the findings from this pilot study by performing a larger observational trial of patients who have not yet undergone treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Diabetic macular edema
- Kodiak begins three phase 3 studies of anti-VEGF antibody biopolymer conjugate, KSI-301 to treat DME and macular edema due to retinal vein occlusionon October 7, 2020 at 12:30 am
VEGF antibody biopolymer conjugate, KSI-301 to treat DME and macular edema due to retinal vein occlusion: Palo Alto, California Wednesd ...
- Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200on October 6, 2020 at 4:30 am
Under this agreement, Kemwell will manage all CMC and clinical manufacturing activities as well as provide OCU200 supplies for IND-enabling toxicology studies and Phase 1/2a clinical trials. Kemwell ...
- Oculis announces presentation of positive results from Phase 2 trial of OCS-01 in patients with Diabetic Macular Edema (DME) at EURETINA 2020 Virtualon October 5, 2020 at 5:10 am
The study met its pre-specified efficacy endpoints and showed that OCS-01 eye drops were more effective than vehicle in reducing central macular ...
- Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosaon October 5, 2020 at 4:04 am
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced the U.S. Food and Drug Administration (FDA) has granted ...
- Diabetic Macular Edema Marketon October 1, 2020 at 6:48 am
The research report on Diabetic Macular Edema Market provides a comprehensive analysis of the market status and development trend, including types, applications, growth, opportunities, rising ...
Go deeper with Google Headlines on:
Diabetic macular edema
Go deeper with Bing News on:
Diabetes related vision loss
- World Sight Day to focus global attention on blindness & vision impairmenton October 5, 2020 at 10:05 pm
World Sight Day is an annual day of awareness, held on the second Thursday of October, to focus global attention on blindness and vision impairment.
- Restoring vision by crippling aberrant blood vessels in the eyeon October 5, 2020 at 12:00 pm
In some forms of retinopathy, blood vessels grow out of control in the eye, blocking light and causing irreversible vision loss. An experimental small molecule blocked proteins in the eye that cause ...
- Living with diabetes? Get your eyes checkedon September 30, 2020 at 5:26 pm
A new University of Sydney study has found only half of people living with diabetes get the recommended diabetes eye checks, putting them at risk ...
- HIV Medications Could Prevent Diabetes: Studyon September 24, 2020 at 2:55 am
Group of drugs used to treat HIV and hepatitis B could be repurposed to prevent type 2 diabetes, a new study suggests.
- Let's Talk About Diabetic Macular Edemaon September 21, 2020 at 2:00 pm
Left untreated, diabetic macular edema can cause permanent vision loss and blindness ... with the possible development of other diabetes-related complications including nephropathy (kidney ...